IJCRR - 17(18), September, 2025
Pages: 01-07
PROTACs for Targeted Protein Degradation: Mechanisms, Design, and Controllable Delivery Strategies
Author: Lukasz Misiak
Category: Healthcare
[Download PDF]
Abstract:
Proteolysis-targeting chimeras (PROTACs) are an emerging class of bifunctional small molecules that induce targeted protein degradation by hijacking the cell’s ubiquitin–proteasome system. A PROTAC simultaneously binds a protein of interest (POI) and an E3 ubiquitin ligase, forming a ternary complex that leads to ubiquitination and proteasomal destruction of the target protein. Here, we present a concise review of PROTAC technology aimed at synthesizing recent advances in mechanism, molecular components, and rational design. Relevant literature was identified through searches of PubMed, Scopus, and Web of Sci ence up to August 2025. Articles were thematically analyzed to highlight mechanistic principles, structure–activity relationships, and delivery innovations. Evidence consistently shows that efficient degradation depends more on productive ternary-complex formation and cooperativity than on binary binding affinities, that linker geometry and E3 ligase choice are decisive factors for selectivity, and that new approaches such as photoswitchable PROTACs, pro-drug designs, and antibody or aptamer conjugates offer spatiotemporal control. The review concludes that standardization of cooperativity metrics, expansion to new E3 ligases, and integration with clinically validated targeting vectors are key priorities for future development.
Keywords: Linker design, Protein degradation, Cancer, Ligands, Clinical trial, Ubiquitin–proteasome system
Citation:
Lukasz Misiak. PROTACs for Targeted Protein Degradation: Mechanisms, Design, and Controllable Delivery Strategies International Journal of Current Research and Review. 17(18), September, 01-07
References:
1. An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-62. doi: 10.1016/j.ebi om.2018.09.005.
2. Wang C, Zhang Y, Yu W, Xu J, Xing D. PROTAC-biomacromol ecule conjugates for precise protein degradation in cancer thera py: A review. Int J Biol Macromol. 2024 Mar;261(Pt 2):129864. doi: 10.1016/j.ijbiomac.2024.129864.
3. Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic — a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-78. doi: 10.1038/s41571-023 00736-3.
4. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degrada tion. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9. doi: 10.1073/pnas.141230798.
5. Schneekloth AR, Pucheault M, Tae HS, Crews CM. Targeted in tracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5904-8. doi: 10.1016/j.bmcl.2008.07.114.
6. Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-mol ecule PROTACs. Nat Chem Biol. 2015 Aug;11(8):611-7. doi: 10.1038/nchembio.1858.
7. Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, et al. Hi jacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. doi: 10.1016/j. chembiol.2015.05.009.
8. Martín-Acosta P, Xiao X. PROTACs to Address the Challenges Facing Small Molecule Inhibitors. Eur J Med Chem. 2021 Jan 15;210:112993. doi: 10.1016/j.ejmech.2020.112993.
9. Shi J, Wang L, Zeng X, Xie C, Meng Z, Campbell A, et al. Pre cision-engineered PROTACs minimize off-tissue effects in can cer therapy. Front Mol Biosci. 2024 Nov 22;11:1505255. doi: 10.3389/fmolb.2024.1505255.
10. Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, et al. An overview of PROTACs: a promising drug discovery paradigm. Mol Bi omed. 2022 Dec 20;3(1):46. doi: 10.1186/s43556-022-00112-0.
11. Kong NR, Jones LH. Clinical Translation of Targeted Protein Degraders. Clin Pharmacol Ther. 2023 Sep;114(3):558-68. doi: 10.1002/cpt.2985.
12. Kiely-Collins H, Winter GE, Bernardes GJL. The role of re versible and irreversible covalent chemistry in targeted protein degradation. Cell Chem Biol. 2021 Jul 15;28(7):952-68. doi: 10.1016/j.chembiol.2021.03.005.
13. Yim J, Park J, Kim G, Lee HH, Chung JS, Jo A, et al. Con ditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation. ChemMedChem. 2024 Nov 18;19(22):e202400326. doi: 10.1002/cmdc.202400326.
14. Bai N, Riching KM, Makaju A, Wu H, Acker TM, Ou SC, et al. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PRO TACs. J Biol Chem. 2022 Apr;298(4):101653. doi: 10.1016/j. jbc.2022.101653.
15. Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: An Emerg ing Targeting Technique for Protein Degradation in Drug Dis covery. Bioessays. 2018 Apr;40(4):e1700247. doi: 10.1002/ bies.201700247.
16. Grigoreva TA, Novikova DS, Melino G, Barlev NA, Tribulovich VG. Ubiquitin recruiting chimera: more than just a PROTAC. Biol Direct. 2024 Jul 9;19(1):55. doi: 10.1186/s13062-024 00497-8.
17. Kubry? N, Fija?kowski ?, Nowaczyk J, Jamil A, Nowaczyk A. PROTAC Technology as a New Tool for Modern Pharmaco therapy. Molecules. 2025 May 11;30(10):2123. doi: 10.3390/ molecules30102123.
18. Moreau K, Coen M, Zhang AX, Pachl F, Castaldi MP, Dahl G, et al. Proteolysis-targeting chimeras in drug development: A safety perspective. Br J Pharmacol. 2020 Apr;177(8):1709-1718. doi: 10.1111/bph.15014.
19. Salami J, Alabi S, Willard RR, Vitale NJ, Wang J, Dong H, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100. doi: 10.1038/s42003-018-0105-8.
20. Edmondson SD, Yang B, Fallan C. Proteolysis targeting chime ras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges. Bioorg Med Chem Lett. 2019 Jul 1;29(13):1555–64. doi: 10.1016/j.bmcl.2019.04.030.
21. Moon Y, Jeon SI, Shim MK, Kim K. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Ap plication to Cancer Immunotherapy. Pharmaceutics. 2023 Jan 26;15(2):411. doi: 10.3390/pharmaceutics15020411.
22. Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022 Jan 5;227:113906. doi: 10.1016/j.ej mech.2021.113906.
23. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, et al. De sign, Synthesis, and Biological Characterization of Metaboli cally Stable Selective Androgen Receptor Modulators. J Med Chem. 2004 Feb 12;47(4):993-8. doi: 10.1021/jm030336u.
24. Guedeney N, Cornu M, Schwalen F, Kieffer C, Voisin-Chiret AS. PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov Today. 2023 Jan;28(1):103395. doi: 10.1016/j.drudis.2022.103395.
25. Wang C, Zheng C, Wang H, Zhang L, Liu Z, Xu P. The state of the art of PROTAC technologies for drug discovery. Eur J Med Chem. 2022 May 5;235:114290. doi: 10.1016/j.ej mech.2022.114290.
26. Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem. 2021 Dec 5;225:113749. doi: 10.1016/j.ejmech.2021.113749.
27. Nowak RP, Ragosta L, Huerta F, Liu H, Ficarro SB, Cruite JT, et al. Development of a covalent cereblon-based PROTAC em ploying a fluorosulfate warhead. RSC Chem Biol. 2023 Aug 31;4(11):906-912. doi: 10.1039/d3cb00103b.
28. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/sci ence.1177319.
29. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodula tory and antiproliferative activities of lenalidomide and poma lidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/ leu.2012.119.
30. Diehl CJ, Ciulli A. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as in hibitors and PROTAC degraders. Chem Soc Rev. 2022 Aug 19;51(19):8216–8257. doi: 10.1039/d2cs00387b
31. Buckley DL, Van Molle I, Gareiss PC, Tae HS, Michel J, Noblin DJ, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc. 2012 Mar 14;134(10):4465-8. doi: 10.1021/ ja209924v.
32. Ohoka N, Okuhira K, Ito M, Nagai K, Shibata N, Hattori T, et al. In vivo knockdown of pathogenic proteins via specific and non genetic Inhibitor of Apoptosis Protein (IAP)-dependent protein erasers (SNIPERs). J Biol Chem. 2017 Mar 17;292(11):4556 70. doi: 10.1074/jbc.M116.768853.
33. Liu X, Yao JJ, Chen Z, Lei W, Duan R, Yao Z. Lipopolysac charide sensitizes the therapeutic response of breast cancer to IAP antagonist. Front Immunol. 2022 Aug 31;13:906357. doi: 10.3389/fimmu.2022.906357.
34. Liu Y, Yang J, Wang T, Luo M, Chen Y, Chen C, et al. Expanding PROTACtable genome universe of E3 ligases. Nat Commun. 2023 Oct 16;14(1):6509. doi: 10.1038/s41467-023-42233-2.
35. Wang C, Zhang Y, Chen W, Wu Y, Xing D. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. Mol Cancer. 2024 May 21;23(1):110. doi: 10.1186/ s12943-024-02024-9.
36. Scheepstra M, Hekking KFW, van Hijfte L, Folmer RHA. Biva lent Ligands for Protein Degradation in Drug Discovery. Com put Struct Biotechnol J. 2019 Jan 25;17:160-76. doi: 10.1016/j. csbj.2019.01.006.
37. Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther. 2020;1(5):273-312. doi: 10.37349/etat.2020.00018.
38. Zattoni J, Vottero P, Carena G, Uliveto C, Pozzati G, Morabito B, et al. A comprehensive primer and review of PROTACs and their In Silico design. Comput Methods Programs Biomed. 2025 Jun;264:108687. doi: 10.1016/j.cmpb.2025.108687.
39. Sincere NI, Anand K, Ashique S, Yang J, You C. PRO TACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies. Molecules. 2023 May 10;28(10):4014. doi: 10.3390/molecules28104014.
40. Dong Y, Ma T, Xu T, Feng Z, Li Y, Song L, et al. Characteris tic roadmap of linker governs the rational design of PROTACs. Acta Pharm Sin B. 2024 Oct;14(10):4266-95. doi: 10.1016/j. apsb.2024.04.007.
41. Salerno A, Wieske LH, Diehl CJ, Ciulli A. Rational design of PROTAC linkers featuring ferrocene as a molecular hinge to en able dynamic conformational changes. J Am Chem Soc. 2025 Apr 23;147(16):13328-44. doi: 10.1021/jacs.4c18354.
42. Crowe C, Nakasone MA, Chandler S, Craigon C, Sathe G, Tatham MH, et al. Mechanism of degrader-targeted protein ubiquitinability. Sci Adv. 2024 Oct 11;10(41):eado6492. doi: 10.1126/sciadv.ado6492.
43. Wurz RP, Rui H, Dellamaggiore K, Ghimire-Rijal S, Choi K, Smither K, et al. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun. 2023 Jul 13;14(1):4177. doi: 10.1038/s41467-023 39904-5.
44. Zoppi V, Hughes SJ, Maniaci C, Testa A, Gmaschitz T, Wieshofer C, et al. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based
|